To develop our approach, we selected monoclonal antibodies currently studied for the development of AML immunotherapies: clone 4G8 (FLT3)16,32, Fab-79D (KIT)15,33 and 7G3 (CD123)34,35. The gene discussed is FLT3; the disease is acute myeloid leukemia.